Welcome to our dedicated page for KalVista Pharmaceuticals SEC filings (Ticker: KALV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KalVista Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KalVista Pharmaceuticals's regulatory disclosures and financial reporting.
KalVista Pharmaceuticals, Inc. disclosed the appointment of Ms. Sensenig as a non-employee director and the associated compensation arrangements. Her initial board award consists of options to purchase 45,000 shares of the company's common stock. She will receive an annual cash retainer of $42,500 plus an additional $10,000 per year for service on the Audit Committee. The disclosure is a routine corporate governance item describing director pay terms.
KalVista Pharmaceuticals, Inc. filed an 8-K reporting the execution of an indenture for a new convertible debt instrument and related press releases. The filing references an indenture dated September 29, 2025 between the company and U.S. Bank Trust Company, N.A., which includes the form of 3.250% Convertible Senior Notes due 2031. The company also filed two press releases dated September 24, 2025 announcing the proposed offering and the pricing of the Notes, and submitted the Cover Page Interactive Data File. The filing is signed by Brian Piekos, Chief Financial Officer.
KalVista Pharmaceuticals, Inc. (KALV) reported mixed operational and clinical disclosures in this 10-Q excerpt. The company had a 100.0 million share registration ("ATM Shares") available under an S-3 prospectus supplement but did not offer or sell any ATM Shares during the three months ended July 31, 2025. Trade accounts receivable arise from product sales to specialty distributors and pharmacies; as of April 30, 2025 the company reported $0 of accounts receivable, net related to product sales and no reserve for credit losses. The filing describes fair value sensitivity for a derivative liability and discloses a $132.3 million royalty obligation as of July 31, 2025, with an embedded derivative carrying a fair value of $9.4 million. A licensing arrangement (Kaken Agreement) included an $11.0 million non-refundable upfront payment, potential regulatory and sales milestones of approximately $13.0 million, and effective royalties in the mid-twenties percent on Japanese pricing, for a 10-year initial term. The company also details commercial terms tied to annual net sales thresholds and a $50.0 million sales-based milestone if sebetralstat achieves at least $550.0 million in annual net sales before 2031. Clinically, EKTERLY (sebetralstat) is described as an oral, on-demand HAE therapy; 600 mg dosing showed statistically significant faster reduction in attack severity (p=0.0032) and faster complete attack resolution (p<0.0001) versus placebo.
KalVista Pharmaceuticals, Inc. filed a current report to share its financial results for the fiscal quarter ended July 31, 2025. The results are contained in a press release furnished as Exhibit 99.1.
The company specifies that this earnings information is furnished under Item 2.02 of the Exchange Act, not deemed filed, and it is signed on behalf of the company by Chief Executive Officer Benjamin L. Palleiko.
Insider transactions by KalVista Pharmaceuticals (KALV): Benjamin L. Palleiko, the company's Chief Executive Officer and a director, received 15,625 restricted stock units (RSUs) on 09/06/2025 that vest in equal quarterly installments (1/16th each) beginning June 6, 2024, and represent one share each on settlement. Upon vesting, 7,294 shares were sold on 09/08/2025 at an average price of $15.84 to satisfy tax-withholding obligations (a "sell to cover"). Following these events he beneficially owns 395,189 shares.
Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals (KALV), reported vesting of 5,000 restricted stock units (RSUs) on 08/22/2025, each convertible into one share upon settlement, increasing her direct common stock holdings to 33,771 shares. A subsequent sell-to-cover transaction on 08/25/2025 disposed of 1,480 shares at $13.42 to satisfy tax-withholding, leaving 32,291 shares held directly. The filing shows 55,000 shares underlying RSUs remain outstanding to the reporting person, with future vesting at 1/16th of the total each quarterly anniversary of the vesting commencement date, subject to continued service.
KalVista Pharmaceuticals (KALV) insider activity: Christopher Yea, the company’s Chief Development Officer and a director, received 3,125 restricted stock units (RSUs) that convert one-for-one into common shares upon settlement. The RSUs were reported as acquired upon vesting and increase the reporting person's contingent claim on 3,125 shares. To satisfy tax withholding when those RSUs settled, the reporting person sold 1,954 shares at $13.42 per share in a "sell-to-cover" transaction, which was not a discretionary sale. After these transactions the reporting person beneficially owned 132,052 common shares and continued to hold RSUs representing 34,375 underlying shares that vest quarterly at one-sixteenth of the total per quarter while service continues.
KalVista Pharmaceuticals insider filing: Chief Medical Officer Audhya Paul K. received 5,000 restricted stock units (RSUs) that vested and settled on 08/22/2025 and represent rights to 5,000 shares. Following that settlement the reporting person beneficially owned 124,841 shares. A subsequent sale of 2,336 shares occurred on 08/25/2025 at a price of $13.42 per share to satisfy tax withholding for the RSU vesting, leaving 122,505 shares beneficially owned. The RSUs vest quarterly at 1/16th of the total and the report shows 55,000 underlying RSUs in total.
Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals (KALV), reported the vesting and settlement of restricted stock units and a subsequent sell-to-cover transaction. On 08/21/2025 she was issued 6,250 shares upon settlement of RSUs, increasing her beneficial ownership to 30,635 shares. On 08/22/2025 she sold 1,864 shares at $13.2228 per share to satisfy tax withholding obligations, leaving 28,771 shares beneficially owned. The filing explains each RSU converts to one share for no consideration and that RSUs vest at a rate of 1/16th of the award on each quarterly anniversary beginning May 21, 2025, subject to continued service.
Nicole Sweeny filed an initial Form 3 reporting her beneficial ownership in KalVista Pharmaceuticals, Inc. (KALV) in her role as Chief Commercial Officer and a director. She holds 100,000 RSUs granted with a vesting schedule that begins May 21, 2025, vesting 1/16th quarterly, and 80,000 RSUs granted with a vesting schedule that began August 22, 2024, vesting 1/16th quarterly. She also holds an employee stock option on 100,000 shares with a stated exercise price of $9.51 and a listed date of 07/24/2033 in the derivative table. The RSUs are described as contingent rights to receive one share upon settlement for no consideration. The Form 3 is signed by an attorney-in-fact, Benjamin Palleiko, dated 08/25/2025.